A 44-year-old male with Ph + chronic myeloid leukaemia (CML) underwent histoidentical allogeneic bone marrow transplantation 18 months after initial diagnosis. He received pretransplant conditioning with busulphan and cyclophosphamide (Bucy). GVHD prophylaxis consisted of methotrexate, cyclosporine (CsA) and methylprednisolone. On day +50, he developed a microangiopathic haemolytic anaemia with indirect bilirubinaemia, 10% fragmented red cells ( 
Bone marrow transplant-associated thrombotic microangiopathy (BMT-TM) is recognized as occurring in up to 6% of patients following bone marrow transplantation (BMT). [1] [2] [3] [4] [5] [6] Several factors may be involved in the pathogenesis of the disorder. These include vascular endothelial damage, platelet aggregation, red cell fragmentation due to microangiopathic haemolysis, CsA treatment and GVHD and/or intensive conditioning therapy. 7 The diagnosis of BMT-TM can be made and graded for severity by using two simple laboratory parameters: LDH value and percentage of fragmented erythrocytes as previously described by Zeigler et al. 1 Patients with grade 2 BMT-TM have been reported to experience resolution either spontaneously or with reduction in cyclosporine dose. By contrast, patients with grades 3-4 BMT-TM do not improve and often die of multiorgan failure. Pettitt factorial fulminate TM, condition-associated haemolyticuraemic syndrome (HUS), CsA-associated nephrotoxicity with microangiopathic haemolytic anaemia (MAHA) and CsA-associated neurotoxicity. Patients with BMT-TM grades 3-4 usually have multifactorial thrombotic microangiopathy post BMT as described by Pettitt and Clark. 8 Treatment of post BMT-TM, especially the poor prognosis multifactorial subtype, is currently unsatisfactory, although occasional cases may respond to plasma exchange. There is some evidence that plasma exchange with infusion of whole plasma (treatment that is highly effective in thrombotic thrombocytopenia purpura (TTP) 9 ) may partially improve the haematologic manifestation in some patients with BMT-TM. [10] [11] [12] However, many patients die of infectious complications in spite of ameloriation of their BMT-TM. Protein A immunoadsorption (PAI), a treatment of some benefit in chemotherapy-induced HUS, has also been of benefit for the occasional patient with BMT-TM. 13 Recently, there has been some success with a program of apheresis that alternates exchanges with replacement with Cryo-poor plasma and PAI over a 2 week period. 10, 12 We report a patient with grade 4 multifactorial BMT-TM who experienced a gratifying clinical response after a prolonged course of exchanges with fresh frozen plasma.
Case report
A 44-year-old male with Ph + CML, received an allo-identical sibling bone marrow transplant following conditioning with busulphan, 4 mg/kg/day × 4 days and cyclosphosphamide, 60 mg/kg/day × 2 days. Graft-versus-host disease prophylaxis was with 3 mg/kg/day cyclosporine, methotrexate, four doses on days +1 (15 mg/m 2 ), +3, +5, +11 (10 mg/m 2 ) and methylprednisolone, 1 mg/kg from day +15, decreasing over 120 days.
Complications during transplantation were grade 3 mucositis, neutropenia and fever which required antibiotic treatment (vancomycin + imipenem + amphotericin B). The days to an absolute neutrophil count of 0.5 × 10 9 /l and a platelet count of greater than 20 × 10 9 /l were 18 and 21, respectively. On day +31 a skin rash that involved 50% of the body was observed. This was documented through biopsy as being acute GVHD grade 2 (histological). Since he had no hepatic or gastrointestinal involvement he was classified clinical stage I. Blood CsA levels were within the therapeutic range (350 ng/ml), and renal and hepatic function were normal. On day +50 weakness, hypertension and edema developed. He had thrombocytopenia (20 × 10 9 /l) anaemia (6 g/l) an elevated LDH level of 1213 U/l, an elevated indirect bilirubin level, and a creatinine of 1.49 mg%.
A clinical diagnosis of thrombotic microangiopathy of multifactorial origin (grade 4) was made and plasmapheresis was performed with replacement with fresh frozen plasma (median exchange volume of 3.850 cm 3 ). During this period the patient continued to receive tapering CsA and steroids. Neither immunoglobulin nor prostaglandins were administered.
The clinical course and laboratory findings are shown in Table 1 .
Results
After 10 procedures there was no response and no progression was observed. Consequently, we continued the procedures. Using the criteria of Zeigler et al the patient had a response to pheresis to the 11th pheresis, with a down-staging of BMT-TM from grade 4 to grade 2, without improvement in the anaemia or thrombocytopenia. Following this, the LDH level continued to fluctuate and pheresis was continued. After the 19th pheresis, the LDH remained lower than 50% of the initial value and progressive improvement in the anaemia and platelet count was seen in spite of discontinuing apheresis.
On day +252, the patient had normal renal function, a creatinine of 1.13 mg%, moderate arterial hypertension, Hb 10.4 g/l, platelets 147 × 10 9 /l, and clinical evidence of chronic GVHD.
Discussion
The role of apheresis in the treatment of high-grade multifactorial BMT-TM is controversial. Llamas et al 14 suggested that only mild multifactorial cases may improve with plasma exchange. Plasma exchange with replacement with fresh frozen plasma (FFP) has been disappointing. 1, 7, 11 The largest experience with FFP exchange was reported by Sarode et al. 11 Most of the experience of exchange with FFP has evaluated courses of exchanges of 1 week or less. It may be noted that the two survivors in the series of patients reported by Sarode et al had undergone 10-28 exchanges. The protocol reported by Zeigler et al [10] [11] [12] employs a 2 week exchange program that alternates exchange with replacement with cryo-poor plasma and PAI. It may also be noted that the patients who survived in the series of patients reported by Silva et al 13 had FFP exchange followed by PAI exchange.
Our patient began to respond to exchange with FFP on the 11th pheresis procedure. With continued exchanges with FFP, he ultimately experienced sustained improvement in the hemoglobin and platelet count. This is contrary to the work of Zeigler et al, [10] [11] [12] where platelet recovery was markedly delayed, even in those patients whose LDH levels and fragmented cells decreased. It is possible that prolonged apheresis has a more important role in the management of fulminant multifactorial BMT-TM rather than does the nature of the apheresis.
